LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma.
about
NLRP3 inflammasome activation promotes inflammation-induced carcinogenesis in head and neck squamous cell carcinoma.Trial watch: Immune checkpoint blockers for cancer therapy.Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma.Next generation immune-checkpoints for cancer therapy.
P2860
LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
LAG-3 confers poor prognosis a ...... neck squamous cell carcinoma.
@en
type
label
LAG-3 confers poor prognosis a ...... neck squamous cell carcinoma.
@en
prefLabel
LAG-3 confers poor prognosis a ...... neck squamous cell carcinoma.
@en
P2093
P2860
P1433
P1476
LAG-3 confers poor prognosis a ...... d neck squamous cell carcinoma
@en
P2093
Ashok B Kulkarni
Guang-Tao Yu
Lin-Lin Bu
Wei-Wei Deng
Wen-Feng Zhang
Zhi-Jun Sun
P2860
P304
P356
10.1080/2162402X.2016.1239005
P577
2016-10-07T00:00:00Z